Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

With a market cap of $736.1 billion, Eli Lilly and Company (LLY) is a leading American pharmaceutical firm headquartered in ...

Looking at its longer-term performance, Eli Lilly's stock appreciated by 422.93% over the past five ... considering the ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

The Dow Jones Industrial Average fell 389.83 points, or 0.95%, to 40,829.00, the S&P 500 lost 43.48 points, or 0.77%, to ...

Wall Street's main indexes opened lower on Tuesday, after U.S. President Donald Trump's latest plans for pharma tariffs further dampened investor sentiment amid subdued corporate earnings.

Looking ahead, the company maintained its sales forecast for revenue ... What is not priced into the stock, though, is the huge potential of orforglipron. That makes Eli Lilly a buy in my book.

Eli Lilly’s (NYSE:LLY) stock faced a notable decline following the company’s announcement of a reduced profit forecast, despite delivering first-quarter results that surpassed Wall Street expectations ...